Carbapenem resistance and phenotypic detection of carbapenemases in clinical isolates of acinetobacter baumannii

Indian Journal of Medical Sciences

Volumn 65, Issue 1, 2010, Pages 18-25

  Mahajan, Gomty ^a   Sheemar, Sheevani ^a   Chopra, Shashi ^a   Kaur, Jaspal ^a   Chowdhary, Deeksha ^a   Makhija, S K ^b  

^a Punjab Institute of Medical Sciences   (India)

^b GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

Acinetobacter baumannii; carbapenemases; mettalo beta lactamases

Indexed keywords

AMIKACIN; CARBAPENEM; CARBAPENEMASE; CEFEPIME; CEFOPERAZONE; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; MEROPENEM; METALLO BETA LACTAMASE; NETILMICIN; PAZUFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; TIGECYCLINE;

ACINETOBACTER BAUMANNII; AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; DISK DIFFUSION; HOSPITAL PATIENT; INTENSIVE CARE UNIT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE;

ACINETOBACTER BAUMANNII; BACTERIAL PROTEINS; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; THIENAMYCINS;

EID: 84870285024     PISSN: 00195359     EISSN: 19983654     Source Type: Journal    
DOI: 10.4103/0019-5359.103161     Document Type: Article

References (30)

1. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006;42:692-9.
2. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin Microbiol Rev 2008;21:538-82.
3. Quale J, Bratu S, Landman D, Heddurshetti R. Molecular epidemiology and mechanisms of carbapenem resistance in acinetobacter baumannii endemic in New York City. Clin Infect Dis 2003;37:214-20.
4. Bou, G, Cervero G, Dominguez MA, Quereda C, Martinez-Beltran J. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: High-level carbapenem resistance in A. baumannii is not due solely to the presence of beta-lactamases. J Clin Microbiol 2000;38:3299-305.
5. Siroy A, Cosette P, Seyer D, Lemaitre-Guillier C, Vallenet D, van Dorsselaer A, et al. Global comparison of the membrane subproteomes between a multidrug-resistant Acinetobacter baumannii strain and a reference strain. J Proteome Res 2006;5:3385-98.
6. Poirel, L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: Mechanisms and epidemiology. Clin Microbiol Infect 2006;12:826-36.
7. Urban C, Segal-Maurer S, Raha JJ. Considerations in control and treatment of nosocomial infections due to multidrug-resistant acinetobacter baumannii. Clin Infect Dis 2003;36:1268-74.
8. Peleg AY, Franklin C, Bell JM, Spelman DW. Disseminationof the metallo-beta-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia. Clin Infect Dis 2005;41:1549-56.
9. Hirakata Y, Izumikawa K, Yamaguchui T, Takemura H, Tanaka H, Yoshida R, et al. Rapid detection and evaluation of clinical characteristics of emerging multiple-drug-resistant Gramnegative rods carrying the metallo-beta lactamase gene blaIMP. Antimicrob Agents Chemother 1998;42:2006-11.
10. Baron EJ, Peterson LR, Finegold SM. Nonfermentative Gram-negative bacilli and coccobacilli. In: Bailey and Scott's diagnostic microbiology. 9th ed. St. Louis, MO: Mosby; 1994. p. 401-2.
11. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement, document M100-S20. Wayne, PA: Clinical Laboratory Standards Institute; 2010. p. 45-110.
12. Lee K, Chong Y, Shin HB, Kim YA, Yong D, Yum JH. Modified Hodge and EDTA-disk synergy tests to screen metallo-β-lactamase-producing strains of Pseudomonas and Acinetobacter species. Clin Microbiol Infect 2001;7:88-91.
13. Franklin C, Liolios L, Peleg AY. Phenotypic detection of carbapenem susceptible MBL-producing gram negative bacilli in the Clinical laboratory. J Clin Microbiol 2006;44:3139-44.
14. Singh AK, Sen MR, Anupurba S, Bhattacharya P. Antibiotic sensitivity pattern of the bacteria isolated from nosocomial infections in ICU. J Commun Dis 2002;34:257-63.
15. Prashanth K, Badrinath S. In vitro susceptibility pattern of acinetobacter species to commonly used cephalosporins, quinolones and aminoglycosides. Indian J Med Microbiol 2004;22:97-103.
16. Anstey NM, Currie BJ, Withnall KM. Communityacquired Acinetobacter pneumonia in the Northern Territory of Australia. Clin Infect Dis 1992;14:83-91.
17. Kucukates E, Kocazeybek B. High resistance rate against 15 different antibiotics in aerobic gramnegative bacteria isolates of cardiology intensive care unit patients. Indian J Med Microbiol 2002;20:208-10.
18. Taneja N, Singh G, Singh M, Sharma M. Emergence of tigecycline & colistin resistant Acinetobacter baumanii in patients with complicated urinary tract infections in north India. Indian J Med Res 2011;133:681-4.
19. Sinha M, Srinivasa H. Mechanisms of resistance to carbapenems in meropenem-resistant Acinetobacter isolates from clinical samples. Indian J Med Microbiol 2007;25:121-5.
20. Uma Karthika R, Srinivasa Rao R, Sahoo S, Shashikala P, Kanungo R, Jayachandran S, et al. Phenotypic and genotypic assays for detecting the prevalence of MBL in clinical isolates of Acinetobacter baumannii from a South Indian tertiary care hospital. J Medical Microbiol 2009;58:430-5.
21. Joshi SG, Litake GM, Niphadkar KB, Ghole VS. Multidrug resistant Acinetobacter baumannii isolates from a teaching hospital. J Infect Chemother 2003;9:187-90.
22. Taneja N, Maharwal S, Sharma M. Imipenem resistance in nonfermenters causing nosocomial urinary tract infections. Indian J Med Sci 2003;57:294-9.
23. Kumar AV, Pillai VS, Dinesh KR, Karim S. The phenotypic detection of carbapenemase in Meropenem resistant acinetobacter Calcoaceticus-Baumannii complex in a Tertiary Care Hospital in South India. J Clin Diagn Res 2011;2:223-6.
24. Jeong SH, Bae IK, Park KO, An YJ, Sohn SG, Jang SJ, et al. Outbreaks of imipenemresistant Acinetobacter baumannii producing carbapenemases in Korea. J Microbiol 2006;44:423-31.
25. Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: Citywide prevalence, inter-institutional spread, and relation to antibiotic usage. Clin Infect Dis 2000;31:101-6.
26. Yong D, Lee K, Yum JH, Shin HB, Rossolini GM, Chong Y. Imipenem-EDTA disk method for differentiation of metallob-lactamase producing clinical isolates of Pseudomonas spp. And Acinetobacter spp. J Clin Microbiol 2002;40:3798-801.
27. Noyal MJ, Menezes GA, Harish BN, Parija SC. Simple screening tests for detection of carbapenemases in clinical isolates of nonfermentative Gram-negative bacteria. Indian J Med Res 2009;129:707-12.
28. Lee K, Lee WG, Uh Y, Ha GY, Cho J, Chong Y. VIM-and IMP-type metallo-β-lactamaseproducing Pseudomonas spp. and Acinetobacter spp spp in Korean hospitals. Emerg Infect Dis 2003;9:868-71.
29. Gupta V, Datta P, Chander J. Prevalence of MBL producing Pseudomonas spp and Acinetobacter spp. spp in a tertiary care hospital in India. J Infect 2006;52:311-4.
30. Lee K, Lim YS, Yong D, Yum JH, Chong Y. Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-beta-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol 2003;4623-9.